PMID- 38503590
OWN - NLM
STAT- Publisher
LR  - 20240319
IS  - 1938-0690 (Electronic)
IS  - 1525-7304 (Linking)
DP  - 2024 Feb 17
TI  - Durvalumab Consolidation After Chemoradiotherapy in Elderly Patients With 
      Unresectable Stage III NSCLC: A Real-World Multicenter Study.
LID - S1525-7304(24)00017-2 [pii]
LID - 10.1016/j.cllc.2024.02.006 [doi]
AB  - BACKGROUND: The PACIFIC trial demonstrated survival benefit of durvalumab after 
      concurrent chemoradiotherapy (CCRT) in unresectable stage III non-small-cell lung 
      cancer. Data on the effectiveness and safety of durvalumab in elderly patients is 
      lacking. METHODS: This retrospective study was conducted between September 2017 
      and September 2022. Progression-free survival (PFS), overall survival (OS), 
      recurrence patterns, first subsequent treatment after recurrence, factors 
      associated with survival outcomes, and adverse events (AEs) were compared. 
      RESULTS: Of the 286 patients, 120 (42.0%) were >/= 70 years and 166 (58.0%) were < 
      70 years. The median PFS (17.7 vs. 19.4 months; P = .43) and median OS (35.7 
      months vs. not reached; P = .13) were similar between 2 groups. Proportion of 
      patients who completed durvalumab was lower in elderly patients (27.5% vs. 39.2%; 
      P = .040). In elderly patients, ECOG PS 0 or 1 was associated with better PFS, 
      and being male and having received a cisplatin-based regimen during CCRT were 
      factors associated with better and worse OS, respectively. In patients aged < 70 
      years, a PD-L1 >/= 50% was associated with improved PFS and OS. Elderly patients 
      experienced more treatment-related AEs, grade 3/4 AEs, permanent discontinuation 
      of durvalumab, and treatment-related deaths. Among the AEs leading to permanent 
      discontinuation or death, pulmonary AE was significantly more common in elderly 
      patients. CONCLUSION: Durvalumab demonstrated similar outcomes in elderly 
      compared to younger patients. However, AEs were more common in elderly patients. 
      Thus, judicious selection of patients and chemotherapy regimens, coupled with 
      careful AE monitoring, are important factors for ensuring optimal durvalumab 
      treatment.
CI  - Copyright (c) 2024 Elsevier Inc. All rights reserved.
FAU - Park, Ji Eun
AU  - Park JE
AD  - Department of Internal Medicine, School of Medicine, Kyungpook National 
      University, Daegu, Republic of Korea.
FAU - Hong, Kyung Soo
AU  - Hong KS
AD  - Department of Internal Medicine, College of Medicine, Yeungnam University, Daegu, 
      Republic of Korea.
FAU - Choi, Sun Ha
AU  - Choi SH
AD  - Department of Internal Medicine, School of Medicine, Kyungpook National 
      University, Daegu, Republic of Korea.
FAU - Lee, Shin Yup
AU  - Lee SY
AD  - Department of Internal Medicine, School of Medicine, Kyungpook National 
      University, Daegu, Republic of Korea.
FAU - Shin, Kyeong-Cheol
AU  - Shin KC
AD  - Department of Internal Medicine, College of Medicine, Yeungnam University, Daegu, 
      Republic of Korea.
FAU - Jang, Jong Geol
AU  - Jang JG
AD  - Department of Internal Medicine, College of Medicine, Yeungnam University, Daegu, 
      Republic of Korea.
FAU - Kwon, Yong Shik
AU  - Kwon YS
AD  - Department of Internal Medicine, School of Medicine, Keimyung University, Busan, 
      Republic of Korea.
FAU - Park, Sun Hyo
AU  - Park SH
AD  - Department of Internal Medicine, School of Medicine, Keimyung University, Busan, 
      Republic of Korea.
FAU - Choi, Keum-Ju
AU  - Choi KJ
AD  - Department of Internal Medicine, College of Medicine, Daegu Catholic University, 
      Daegu, Republic of Korea.
FAU - Jung, Chi Young
AU  - Jung CY
AD  - Department of Internal Medicine, College of Medicine, Daegu Catholic University, 
      Daegu, Republic of Korea.
FAU - Eom, Jung Seop
AU  - Eom JS
AD  - Department of Internal Medicine, College of Medicine, Pusan National University, 
      Busan, Republic of Korea.
FAU - Kim, Saerom
AU  - Kim S
AD  - Department of Internal Medicine, College of Medicine, Pusan National University, 
      Busan, Republic of Korea.
FAU - Seol, Hee Yun
AU  - Seol HY
AD  - Department of Internal Medicine, College of Medicine, Pusan National University, 
      Busan, Republic of Korea.
FAU - Kim, Jehun
AU  - Kim J
AD  - Department of Internal Medicine, College of Medicine, Kosin University College of 
      Medicine, Busan, Republic of Korea.
FAU - Kim, Insu
AU  - Kim I
AD  - Department of Internal Medicine, College of Medicine, Dong-A University, Busan, 
      Republic of Korea.
FAU - Park, Jin Han
AU  - Park JH
AD  - Department of Internal Medicine, College of Medicine, Inje University, Busan, 
      Republic of Korea.
FAU - Kim, Tae Hoon
AU  - Kim TH
AD  - Department of Internal Medicine, School of Medicine, Gyeongsang National 
      University, Changwon, Republic of Korea.
FAU - Ahn, June Hong
AU  - Ahn JH
AD  - Department of Internal Medicine, College of Medicine, Yeungnam University, Daegu, 
      Republic of Korea. Electronic address: fireajh@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20240217
PL  - United States
TA  - Clin Lung Cancer
JT  - Clinical lung cancer
JID - 100893225
SB  - IM
OTO - NOTNLM
OT  - Non-small cell lung cancer
OT  - Real-world data
COIS- Disclosure The authors declare that they have no known competing financial 
      interests or personal relationships that could have appeared to influence the 
      work reported in this paper.
EDAT- 2024/03/20 00:42
MHDA- 2024/03/20 00:42
CRDT- 2024/03/19 22:58
PHST- 2023/12/09 00:00 [received]
PHST- 2024/01/29 00:00 [revised]
PHST- 2024/02/11 00:00 [accepted]
PHST- 2024/03/20 00:42 [medline]
PHST- 2024/03/20 00:42 [pubmed]
PHST- 2024/03/19 22:58 [entrez]
AID - S1525-7304(24)00017-2 [pii]
AID - 10.1016/j.cllc.2024.02.006 [doi]
PST - aheadofprint
SO  - Clin Lung Cancer. 2024 Feb 17:S1525-7304(24)00017-2. doi: 
      10.1016/j.cllc.2024.02.006.